- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02801188
Effect of Dexmedetomidine and Bupivacaine for Paravertebral Block
Evaluation Effect of Adding Dexmedetomidine to Bupivacaine for Paravertebral Block in Femoral Fractures
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Fracture femur is a common injury which is associated with excruciating pain . This pain is one of the most important causes of postoperative morbidity and mortality when it is insufficiently treated pain. Pain induces neuroendocrine stress response causing problems like as reduction in vital capacity, pneumonia, tachycardia, hypertension, myocardial ischemia and even infarction. These problems can be prevented by successful management of postoperative pain.
In patients with proximal femoral fracture, the use of paravertebral blockade produces reliable level of analgesia without need for additional nursing skills or monitoring in the postoperative period. Paravertebral blockade by injection local anesthetic solution alongside the vertebral column produces ipsilateral analgesia.
Currently available local anesthetics as bupivacaine may not provide reliable periods of analgesia resulting in block resolution before the period of worst postoperative pain. The use of a large volume of local anesthetic is one of methods to overcome this problem that may lengthen the duration of analgesia but at increased risk of local anesthetic toxicity. Adding adjuvants is another potential alternative.
Dexmedetomidine, a selective α 2 agonist, has been used to prolong the duration of analgesia of nerve blocks. Dexmedetomidine has also been reported to enhance central and peripheral nerve blockade. Alpha adrenoceptors located at the nerve endings have a possible role in the analgesic mechanisms by preventing norepinephrine release. The spinal mechanism is the principle mechanism for the analgesic action of dexmedetomidine.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
DK
-
Mansoura, DK, Egypt, 050
- Mansoura University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- American Society of Anesthesiologists physical class I or II
Exclusion Criteria:
- Patient refusal.
- Severe or uncompensated cardiovascular disease.
- Severe or uncompensated renal disease.
- Severe or uncompensated hepatic disease.
- Severe or uncompensated endocrinal disease.
- Pregnancy.
- Postpartum ladies.
- Lactating females.
- Allergy to any of the study medications .
- Coagulation disorders.
- Infection at the site of needle insertion
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Bupivacaine group
Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
|
Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
|
Aktiv komparator: Mixture of bupivacaine and dexmedetomidine group
Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
|
Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Scale for radiological spread of the injectate
Tidsramme: for 20 min after performing the blockade
|
It will be assessed using the following scale -2; spread for two vertebral levels below the site of injection, -1; spread for one vertebral level below the site of injection, 0; stays at the level of injection, +2; spread for two vertebral levels above the site of injection, +1; spread for one vertebral level above the site of injection
|
for 20 min after performing the blockade
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pain scores
Tidsramme: For 48 hours after surgery
|
The severity of pain will be assessed using a visual analog scale (VAS)
|
For 48 hours after surgery
|
Duration of postoperative analgesia
Tidsramme: for 24 hours after surgery
|
The period from completion of the block to time of administration of the first request of rescue analgesic for postoperative pain will be recorded
|
for 24 hours after surgery
|
Postoperative analgesic consumption
Tidsramme: for 48 hours after surgery
|
Total postoperative analgesic consumption
|
for 48 hours after surgery
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Reem A El sharkawy, MD, Department of Anaesthesia, Surgical Intensive Care and Pain Medicine, College of Medicine, Mansoura University, Mansoura, Egypt
- Studieleder: Mohamed Y Makharita, MD, Department of Anaesthesia, Surgical Intensive Care and Pain Medicine, College of Medicine, Mansoura University, Mansoura, Egypt
- Studiestol: Nabil Abd-El Raouf, MD, Department of Anaesthesia, Surgical Intensive Care and Pain Medicine, College of Medicine, Mansoura University, Mansoura, Egypt
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sår og skader
- Brudd, bein
- Fysiologiske effekter av legemidler
- Adrenerge midler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Sentralnervesystemdepressiva
- Agenter fra det perifere nervesystemet
- Analgetika
- Sensoriske systemagenter
- Bedøvelsesmidler
- Analgetika, ikke-narkotisk
- Adrenerge alfa-2-reseptoragonister
- Adrenerge alfa-agonister
- Adrenerge agonister
- Hypnotika og beroligende midler
- Anestesimidler, lokal
- Dexmedetomidin
- Bupivakain
Andre studie-ID-numre
- MD ∕ 128
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Fracture of Proximal Femur
-
Zimmer BiometAvsluttetFemur brudd | Garden Grade I Subcapital Fracture of Femoral Neck | Garden Grade II Subcapital Fracture of Femoral Neck | Femur Fracture Intertrochanteric | Garden Grade III Subcapital Fracture of Femoral Neck | Garden Grade IV Subcapital Fracture of Femoral NeckForente stater
-
Zimmer BiometAvsluttetIntrakapsulær proksimal femurfraktur | Garden Grade I Subcapital Fracture of Femoral Neck | Garden Grade II Subcapital Fracture of Femoral NeckForente stater
Kliniske studier på Bupivacaine
-
Universitas PadjadjaranFullførtSmerter, postoperativt | NerveblokkIndonesia
-
University Hospital Plymouth NHS TrustAvsluttet
-
Assiut UniversityHar ikke rekruttert ennå
-
Dr. Lutfi Kirdar Kartal Training and Research HospitalPåmelding etter invitasjon
-
Başakşehir Çam & Sakura City HospitalFullførtAnestesi, lokal | Postoperativ smerte | Hoftebrudd | QoR-15Tyrkia
-
State University of New York - Upstate Medical...Fullført
-
Sisli Hamidiye Etfal Training and Research HospitalFullført
-
Benha UniversityFullført
-
Ankara City Hospital BilkentHar ikke rekruttert ennåHoftebrudd | Spinal anestesi
-
University Tunis El ManarRekrutteringPostoperativ smerte | Analgesi | Anestesi, lokal | UnderkjevebruddTunisia